ARVN241220P35000
- 0.00
- 0.000.00%
Arvinas Newsroom
BMO Capital Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $88
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Arvinas Holding's VERITAC-2 Trial Progress Drives Buy Rating Despite Adjusted Price Target
Arvinas Is Maintained at Outperform by BMO Capital
Arvinas Price Target Cut to $88.00/Share From $90.00 by BMO Capital
BMO Capital Maintains Arvinas(ARVN.US) With Buy Rating, Cuts Target Price to $88
Stephens Initiates Arvinas(ARVN.US) With Buy Rating, Announces Target Price $55
Arvinas Analyst Ratings
Stephens & Co. Initiates Coverage On Arvinas With Overweight Rating, Announces Price Target of $55
Analysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), 2seventy Bio (TSVT)
Morgan Stanley Maintains Arvinas(ARVN.US) With Hold Rating, Maintains Target Price $48
UBS Maintains Arvinas(ARVN.US) With Buy Rating, Cuts Target Price to $74
Arvinas Price Target Maintained With a $87.00/Share by HC Wainwright & Co.
Stifel Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $63
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $40 to $87
Arvinas Analyst Ratings
Jefferies Maintains Arvinas(ARVN.US) With Buy Rating, Cuts Target Price to $60
Stifel Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $63
Arvinas Holding Company (ARVN) Receives a Buy From Stifel Nicolaus
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60